Ratings Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.745 ^USD	+12.98%		-9.10%	+6.39%

Apr. 18	Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ
Apr. 18	Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
OCULAR THERAPEUTIX, INC.	+6.39%	734M	C-
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+26.14%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+14.51%	231B	B+
NOVARTIS AG	+5.24%	200B	B-
ROCHE HOLDING AG	-9.04%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes